|Coordinator||BrainCool AB (publ)|
|Funding from Vinnova||SEK 500 000|
|Project duration||December 2018 - August 2019|
Purpose and goal
The objective of this project is to conduct a feasibility study of the CoolPrevent System, for prevention of OM (Cooral) and prevention of CIPN (CooLimb). The goal is to finalize the technical, clinical and commercial plans required for successful market entry. BrainCool will: 1. Define technical requirements of the final CooLimb design via user studies, 2. Define the segments of target population from market entry of both Cooral® and CooLimb, 3. Define the clinical plan for CooLimb (for FDA-approval and marketing) and Cooral® (for marketing), 4. Define the pricing strategy.
Expected results and effects
The effect and the result of the study is consolidating all findings from the feasibility study in a detailed business plan for raising of funds either through investors or non-dilutive funding such as the SME Phase 2 program within Horizon 2020.
Planned approach and implementation
The study will be conducted with four well-defined targets / workplaces. It will be conducted in close collaboration with two major key opinion leaders (KOL) / institutions from Sweden, two from the US and one from Japan to be able to detect regional variances, even though the initial market will be on Europe.